COLUMBIA, MD (1/8/07) --- Dr. Bruce Littman, former Vice President and Global Head of Translational Medicine at Pfizer, has joined the Board of Directors at BioFortis.
Dr. Littman spent the past 19 years at Pfizer, where he led efforts on applying the value of translational research to improve the drug development process.
“Bruce brings critical experience that will help guide BioFortis as we leverage our success in supporting translational research into the pharmaceutical sector,” says Jian Wang, CEO of BioFortis. “We are pleased to have attracted a board member of Dr. Littman’s caliber.”
“There is a strong synergy between drug researchers seeking to identify the most efficient tools for developing personalized medicines and BioFortis’ mission in supporting translational research,” notes Dr. Littman. “By simplifying the ability to link biomarker and other types of lab data with biological and clinical information, BioFortis should find a ready market for their products in the pharmaceutical and biotech industries.”
Prior to joining Pfizer, Dr. Littman was head of rheumatology at the Richmond VA Hospital and Professor of Medicine at Medical College of Virginia.
He received post-graduate training in internal medicine, rheumatology and immunology at Tufts New England Medical Center, Harvard Medical School, and the National Cancer Institute.
About BioFortis BioFortis is a privately-held company focused on providing biomedical research software and services to the life sciences sector, including government and academic research institutes and the biopharmaceutical industry. BioFortis’ flagship product Labmatrix(tm), supports translational medicine initiatives with applications in clinical research, biobanking and biomarker discovery. Labmatrix enables transparent data management, integration, collaboration and compliance to privacy regulations.
